Seven biotech unicorns are advancing AI-powered drug discovery and development—but must contend with a difficult investing ...

There is a Strong Business Case for Phase II Clinical Program for Treatment of MPox Infection Using NV-387, an Industry-Leading Broad-Spectrum Antiviral Drug Candidate ...

Partnership established to develop and scale production of ATL-105, a novel recombinant version of alpha-1 antitrypsin ...

Dr. Zuraw led clinical development of telitacicept across MG, Sjögren’s, SLE, and RA at RemeGen, resulting in multiple ...

A key House committee has blocked a bipartisan amendment to a spending bill that would have given the Department of Defense ...

The success is a result of the partnership between itWorks Learning Center, MOED and Catholic Charities’ Compassionate Caregivers and Level Up programs.

Organon & Co. (NYSE:OGN) is one of the 13 Cheap Healthcare Stocks with Huge Upside Potential. On July 2, Organon & Co. (NYSE:OGN) announced that its Phase 2 ELENA proof-of-concept study did not meet ...

A Clinical Trial Application is in development with many parts having been substantially completed. NanoViricides has engaged a Clinical Research Organization (CRO) to organize and conduct this ...